Taking stock of the drug industry, from the lab to the medicine chestMay 2, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Yichuan Cao/Sipa USA via AP Images STAT+ | Gilead gets a boost from California court in a case over slow-walking an HIV drug The move by the California Supreme Court to review the case is seen as "very important," according Evercore ISI analyst Umer Raffat. By Ed Silverman STAT+ | Novo Nordisk defends Ozempic's price in face of Senate scrutiny Novo fielded several questions about pricing on its earnings call, after Sen. Bernie Sanders launched an investigation into Ozempic, Wegovy. By Elaine Chen STAT+ | Novartis extends radiopharma plans with $1 billion acquisition The acquisition presents a new avenue for Novartis, which already sells the leading radiopharmaceutical drug, Pluvicto. By Allison DeAngelis Wikimedia Commons STAT+ | DEA reverses a policy to avert morphine shortages The agency is allowing annual and semi-annual production quotas for Schedule II drugs, after it became clear quarterly quotas would worsen shortages. By John Wilkerson STAT+ | BridgeBio spins out oncology company as it focuses on heart drug BridgeBio is spinning out its oncology subsidiary as it gears up for the anticipated launch of its drug for the heart disease ATTR-CM. By Elaine Chen Listen: Controversial brain tissue research, obesity drug sales, and Novartis' M&A drama In this episode, we discuss Novartis' effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk's obesity drugs. By Adam Feuerstein and Allison DeAngelis More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments